{"id":"cdp870","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tuberculosis reactivation risk"}]},"_chembl":{"chemblId":"CHEMBL1201831","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CDP870 (certolizumab pegol) is a TNF-alpha antagonist composed of a humanized anti-TNF monoclonal antibody fragment conjugated to polyethylene glycol (PEG). The pegylation increases the drug's half-life and reduces immunogenicity while maintaining its ability to bind TNF-alpha and prevent its interaction with TNF receptors on immune cells, thereby suppressing inflammatory signaling.","oneSentence":"CDP870 is a pegylated TNF-alpha inhibitor that binds and neutralizes tumor necrosis factor-alpha to reduce inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:03.977Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"}]},"trialDetails":[{"nctId":"NCT04123795","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2020-01-21","conditions":"Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis","enrollment":49},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT02714881","phase":"","title":"Lipids, Inflammation, and CV Risk in RA","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-10-17","conditions":"Rheumatoid Arthritis, Cardiovascular Disease","enrollment":74},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT04991025","phase":"PHASE2","title":"Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-10-19","conditions":"Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III","enrollment":60},{"nctId":"NCT06028438","phase":"PHASE2","title":"A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-08-15","conditions":"Arthritis, Rheumatoid","enrollment":103},{"nctId":"NCT05379322","phase":"PHASE3","title":"The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients","status":"WITHDRAWN","sponsor":"Abu Dhabi Stem Cells Center","startDate":"2023-03-01","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT07149792","phase":"PHASE4","title":"A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-07-29","conditions":"Psoriasis, Psoriasis Arthritis, Biologics","enrollment":50},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT04891640","phase":"NA","title":"Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-11-11","conditions":"Juvenile Spondyloarthritis","enrollment":164},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT03559660","phase":"","title":"CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)","status":"NO_LONGER_AVAILABLE","sponsor":"UCB Biopharma SRL","startDate":"","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT03559686","phase":"","title":"Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)","status":"AVAILABLE","sponsor":"UCB Biopharma SRL","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis","enrollment":841},{"nctId":"NCT04571697","phase":"","title":"A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-28","conditions":"Dementia, Alzheimer Disease","enrollment":34647},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT01797224","phase":"","title":"OTIS Cimzia Pregnancy Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2012-03","conditions":"Crohn's Disease, Rheumatoid Arthritis, Ankylosing Spondylitis","enrollment":925},{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":"Psoriasis, Psoriatic-arthritis","enrollment":3500},{"nctId":"NCT03546335","phase":"PHASE1","title":"Zr-89 Cimzia PET Imaging Rheumatoid Arthritis","status":"SUSPENDED","sponsor":"Robert Flavell, MD, PhD","startDate":"2018-10-01","conditions":"Rheumatoid Arthritis","enrollment":10},{"nctId":"NCT03152058","phase":"PHASE2","title":"IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy","status":"RECRUITING","sponsor":"David Ware Branch","startDate":"2017-05-17","conditions":"High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy","enrollment":55},{"nctId":"NCT01451203","phase":"PHASE3","title":"Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-10-11","conditions":"Rheumatoid Arthritis","enrollment":319},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT02674308","phase":"","title":"Entyvio (Vedolizumab) Long Term Safety Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-03-24","conditions":"Ulcerative Colitis and Crohn's Disease","enrollment":5302},{"nctId":"NCT01550003","phase":"PHASE3","title":"Pediatric Arthritis Study of Certolizumab Pegol","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2012-03-08","conditions":"Polyarticular-course Juvenile Idiopathic Arthritis (JIA)","enrollment":193},{"nctId":"NCT04163016","phase":"PHASE1","title":"A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2020-06-19","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease","enrollment":22},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT04740814","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2021-02-11","conditions":"Rheumatoid Arthritis","enrollment":33},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT05930613","phase":"PHASE3","title":"Certolizumab in Recurrent Implantation Failure (RIF)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-11-30","conditions":"Recurrent Unexplained Implantation Failure","enrollment":161},{"nctId":"NCT05702879","phase":"","title":"Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success","status":"UNKNOWN","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-09-06","conditions":"Ulcerative Colitis","enrollment":240},{"nctId":"NCT03293784","phase":"PHASE1","title":"TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2017-10-16","conditions":"Melanoma","enrollment":33},{"nctId":"NCT03215277","phase":"PHASE2","title":"A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-10-04","conditions":"Ankylosing Spondylitis","enrollment":76},{"nctId":"NCT05014555","phase":"","title":"Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"GI Alliance","startDate":"2023-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":400},{"nctId":"NCT00844285","phase":"","title":"SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2009-01-30","conditions":"Crohn's Disease","enrollment":3072},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT03266471","phase":"","title":"Cytokines and Genes in Therapeutic Response in Crohn's Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2017-10-13","conditions":"Inflammatory Bowel Diseases","enrollment":96},{"nctId":"NCT02120807","phase":"PHASE1","title":"Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-04-15","conditions":"Stage IV Lung Adenocarcinoma","enrollment":30},{"nctId":"NCT04053881","phase":"","title":"A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-08-21","conditions":"Plaque Psoriasis","enrollment":412},{"nctId":"NCT05651373","phase":"","title":"The Clinical Features and Pregnancy Outcomes of RA Patients","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-07-30","conditions":"Rheumatoid Arthritis, Pregnancy Related","enrollment":100},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT02620189","phase":"","title":"Th17 Responses Evaluated in RA Patients on Inhibitors of TNFα","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2015-03","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT03100253","phase":"PHASE4","title":"Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-03-01","conditions":"Rheumatoid Arthritis","enrollment":208},{"nctId":"NCT02552212","phase":"PHASE3","title":"Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2015-09","conditions":"Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA","enrollment":317},{"nctId":"NCT01491815","phase":"PHASE4","title":"Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2012-12-14","conditions":"Rheumatoid Arthritis","enrollment":812},{"nctId":"NCT02466581","phase":"PHASE4","title":"Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2015-02-03","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":"Psoriasis","enrollment":17743},{"nctId":"NCT04798287","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-10","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT01197066","phase":"PHASE3","title":"Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-03","conditions":"Rheumatoid Arthritis","enrollment":110},{"nctId":"NCT04378621","phase":"NA","title":"Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2020-10-01","conditions":"Rheumatoid Arthritis, Pain, Fatigue","enrollment":212},{"nctId":"NCT02619552","phase":"","title":"Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-08","conditions":"Crohn's Disease, IBD","enrollment":50},{"nctId":"NCT04772248","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-22","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT03955861","phase":"","title":"Ultrasound Enthesitis Response in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Belfast Health and Social Care Trust","startDate":"2019-02-14","conditions":"Psoriatic Arthritis, Psoriasis, Enthesitis","enrollment":80},{"nctId":"NCT03051217","phase":"PHASE2, PHASE3","title":"A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2017-02-21","conditions":"Moderate to Severe Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis","enrollment":127},{"nctId":"NCT01090154","phase":"PHASE2","title":"Study of Cimzia for the Treatment of Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2010-12-01","conditions":"Ulcerative Colitis","enrollment":27},{"nctId":"NCT05119452","phase":"NA","title":"Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2022-03","conditions":"Rheumatoid Arthritis","enrollment":85},{"nctId":"NCT02346240","phase":"PHASE3","title":"Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2015-02-11","conditions":"Psoriasis, Plaque Psoriasis","enrollment":559},{"nctId":"NCT04643483","phase":"PHASE3","title":"A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease","status":"WITHDRAWN","sponsor":"UCB Biopharma SRL","startDate":"2021-06","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02775656","phase":"","title":"UCB Cimzia Pregnancy Follow-up Study","status":"TERMINATED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2016-11","conditions":"Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA)","enrollment":1},{"nctId":"NCT03020992","phase":"PHASE4","title":"A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2016-12-21","conditions":"Axial Spondyloarthritis (axSpA), Anterior Uveitis (AU)","enrollment":89},{"nctId":"NCT01764321","phase":"","title":"Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":1723},{"nctId":"NCT01190410","phase":"PHASE2","title":"Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-08","conditions":"Crohn's Disease","enrollment":16},{"nctId":"NCT02505542","phase":"PHASE3","title":"Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2015-07","conditions":"Axial Spondyloarthrithis, Ankylosing Spondylitis","enrollment":736},{"nctId":"NCT00152386","phase":"PHASE3","title":"A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-02","conditions":"Rheumatoid Arthritis","enrollment":950},{"nctId":"NCT01602302","phase":"PHASE4","title":"Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Medical University of Graz","startDate":"2012-06","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT00160602","phase":"PHASE3","title":"A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-06","conditions":"Rheumatoid Arthritis","enrollment":590},{"nctId":"NCT01548768","phase":"PHASE4","title":"RHYTHM (Formerly Escape II Myocardium)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2011-10-10","conditions":"Rheumatoid Arthritis","enrollment":149},{"nctId":"NCT02755194","phase":"","title":"\"Drugs in Lactation\" Analysis Consortium","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2014-09","conditions":"Lactation","enrollment":68},{"nctId":"NCT02353780","phase":"PHASE4","title":"Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept","status":"TERMINATED","sponsor":"Dr. Larry W. Moreland","startDate":"2015-03","conditions":"Rheumatoid Arthritis (RA)","enrollment":10},{"nctId":"NCT04569890","phase":"NA","title":"Treatment of Pregnancy RA","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-12-01","conditions":"Rheumatoid Arthritis, Pregnancy Related","enrollment":100},{"nctId":"NCT00291668","phase":"PHASE2","title":"Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-03-02","conditions":"Crohn's Disease","enrollment":94},{"nctId":"NCT01095393","phase":"","title":"National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-09-01","conditions":"Rheumatoid Arthritis","enrollment":12500},{"nctId":"NCT00160641","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-11","conditions":"Rheumatoid Arthritis","enrollment":567},{"nctId":"NCT00175877","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-06","conditions":"Rheumatoid Arthritis","enrollment":857},{"nctId":"NCT01864265","phase":"PHASE3","title":"Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2013-07","conditions":"Rheumatoid Arthritis","enrollment":156},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT03016260","phase":"","title":"RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"TcLand Expression S.A.","startDate":"2016-12","conditions":"RheumatoId Arthritis","enrollment":250},{"nctId":"NCT02326298","phase":"PHASE3","title":"An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2014-12-16","conditions":"Psoriasis, Plaque Psoriasis","enrollment":234},{"nctId":"NCT03357471","phase":"PHASE3","title":"Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2017-11-03","conditions":"Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis","enrollment":70},{"nctId":"NCT02326272","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2014-12-15","conditions":"Psoriasis, Plaque Psoriasis","enrollment":227},{"nctId":"NCT02778789","phase":"","title":"Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2015-10","conditions":"Rheumatoid Arthritis","enrollment":66},{"nctId":"NCT03775824","phase":"","title":"Faecal Analyses in Rheumatoid Arthritis Therapy","status":"COMPLETED","sponsor":"Region Skane","startDate":"2016-08-01","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT01590966","phase":"PHASE3","title":"Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2012-10-18","conditions":"Axial and Peripheral Spondyloarthritis, Rheumatoid Arthritis","enrollment":41},{"nctId":"NCT02019602","phase":"PHASE1","title":"A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2014-01","conditions":"Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis","enrollment":37},{"nctId":"NCT03553472","phase":"","title":"Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-01-01","conditions":"Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease","enrollment":97},{"nctId":"NCT00329303","phase":"PHASE2","title":"Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-04","conditions":"Psoriasis","enrollment":71},{"nctId":"NCT00245765","phase":"PHASE2","title":"Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-10","conditions":"Chronic Plaque Psoriasis","enrollment":176},{"nctId":"NCT02354105","phase":"","title":"A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2015-01-12","conditions":"Axial Spondyloarthritis","enrollment":680},{"nctId":"NCT01773681","phase":"","title":"Novel Imaging Markers for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2013-10","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT02434133","phase":"","title":"Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2015-04","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":110},{"nctId":"NCT02319642","phase":"PHASE3","title":"An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2014-11","conditions":"Rheumatoid Arthritis","enrollment":347},{"nctId":"NCT00552344","phase":"PHASE3","title":"A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2008-05","conditions":"Crohn Disease","enrollment":403},{"nctId":"NCT00349752","phase":"PHASE3","title":"Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease","status":"TERMINATED","sponsor":"UCB Pharma","startDate":"2006-11","conditions":"Crohn's Disease","enrollment":174},{"nctId":"NCT00356408","phase":"PHASE3","title":"Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-01","conditions":"Crohn's Disease","enrollment":106},{"nctId":"NCT00552058","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-03","conditions":"Crohn Disease","enrollment":439},{"nctId":"NCT00899678","phase":"PHASE2","title":"The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents","status":"TERMINATED","sponsor":"UCB Celltech","startDate":"2009-04","conditions":"Crohn's Disease","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CDP870","genericName":"CDP870","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CDP870 is a pegylated TNF-alpha inhibitor that binds and neutralizes tumor necrosis factor-alpha to reduce inflammatory responses. Used for Rheumatoid arthritis, Crohn's disease, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}